How India Exports Nitrofurantoin to the World

In the United States, nitrofurantoin has been approved by the FDA in various formulations, including oral suspensions and tablets. The brand name Furadantin, for instance, received approval for its 25 mg/5 mL oral suspension prior to January 1, 1982, and for its 50 mg/5 mL formulation on June 9, 2023. Generic versions of Furadantin have also been approved; however, FDA approval does not guarantee immediate market availability.

The substantial export volume of nitrofurantoin from India to the U.S. underscores the importance of compliance with FDA regulations. Indian exporters must adhere to stringent quality standards, including Good Manufacturing Practices (GMP), to ensure market access and maintain the trust of U.S. importers.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products, including nitrofurantoin. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines meet applicable standards of safety, quality, and efficacy. Manufacturers exporting to these regions must comply with EU GMP requirements, which encompass rigorous standards for production, quality control, and quality assurance.

Nitrofurantoin is listed in the WHO Model List of Essential Medicines, underscoring its significance in addressing priority health care needs globally. The 24th edition of the list, published in September 2025, includes nitrofurantoin as a key antibacterial agent. (who.int) This inclusion highlights the drug's critical role in treating urinary tract infections worldwide.

Regarding pharmacopoeial standards, nitrofurantoin is monographed in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, purity, and potency of the drug across different markets.

In India, nitrofurantoin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. This classification mandates that nitrofurantoin can only be sold by retail on the prescription of a registered medical practitioner.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines in India. As of the latest updates, nitrofurantoin is subject to price control measures to ensure affordability and accessibility. Exporters are also required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of certain pharmaceutical products, ensuring that domestic needs are not compromised.

Nitrofurantoin has been available for several decades, and its primary patents have long expired. This has led to the presence of multiple generic versions in the market, fostering competition and making the drug more accessible and affordable globally.

In June 2023, the FDA approved a new 50 mg/5 mL oral suspension formulation of Furadantin, expanding the available treatment options for patients.

In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, reaffirming nitrofurantoin's status as an essential medicine for treating urinary tract infections. (who.int)

These developments reflect the ongoing global recognition of nitrofurantoin's importance in treating urinary tract infections and the continuous efforts to ensure its availability and compliance with international standards.

India's pharmaceutical industry, including the production of Nitrofurantoin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian pharmaceutical manufacturing are sourced from China, making the supply chain vulnerable to disruptions. This dependency was highlighted in June 2024 when environmental regulations led to the shutdown of several Chinese chemical plants, causing significant supply shortages and price increases for Indian manufacturers.

Efforts to reduce this reliance have been initiated, such as India's Production Linked Incentive (PLI) scheme launched in 2024, aiming to bolster domestic production of critical APIs and KSMs. However, as of November 2024, the impact of these initiatives remains limited, with India still importing a substantial portion of its pharmaceutical raw materials from China.

The export market for Nitrofurantoin is highly concentrated, with the top five Indian exporters accounting for 72.8% of total exports. MANKIND PHARMA LIMITED alone holds a 38.1% share, exporting $13.0 million worth of Nitrofurantoin. This concentration poses a significant risk; any operational or regulatory issues affecting these key suppliers could disrupt the global supply chain.

The PLI scheme, introduced to encourage domestic production of APIs and reduce import dependence, has seen some progress. By November 2024, two new manufacturing units were inaugurated under this scheme, focusing on producing essential molecules for antibiotics. While these developments are promising, the overall impact on reducing supplier concentration in the Nitrofurantoin market is yet to be realized.

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical exports. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the movement of oil and other goods, including pharmaceuticals. This blockade led to increased shipping costs and delays, affecting the timely delivery of drugs like Nitrofurantoin.

Additionally, instability in the Red Sea region has forced shipping companies to reroute vessels around the Cape of Good Hope, adding approximately 10 to 14 days to transit times. These disruptions have strained supply chains, leading to potential shortages and increased prices for essential medications.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country.

• Strengthen Domestic Production: Accelerate initiatives like the PLI scheme to enhance local manufacturing capabilities for critical pharmaceutical ingredients.

• Enhance Supplier Audits: Implement rigorous quality control and compliance checks for key suppliers to mitigate risks associated with regulatory violations.

• Develop Contingency Shipping Plans: Establish alternative logistics strategies to navigate geopolitical disruptions, ensuring consistent delivery schedules.

• Monitor Geopolitical Developments: Stay informed about international conflicts and their potential impact on supply chains to proactively address emerging risks.

RISK_LEVEL: HIGH